NCT00472927View on ClinicalTrials.gov

Bioequivalence Study of 3 New Formulations of Premarin/MPA Compared With Premarin/MPA (Prempro)

PHASE1CompletedINTERVENTIONAL
Timeline

Start Date

May 31, 2007

Study Completion Date

August 31, 2007

Conditions
Postmenopause
Interventions
DRUG

Premarin/MPA 0.45 mg/1.5 mg

Trial Locations (1)

33126

Miami

All Listed Sponsors
lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00472927 - Bioequivalence Study of 3 New Formulations of Premarin/MPA Compared With Premarin/MPA (Prempro) | Biotech Hunter | Biotech Hunter